TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
A phase 3 trial of Mobocertinib, Pemetrexed, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Takeda, active and no longer recruiting.
Overview
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations is a phase 3 interventional study registered as NCT04129502 by Takeda, with 354 participants enrolled, started 2020-01-10 and due to reach its primary completion in 2026-10-31. Interventions recorded: TAK-788, Pemetrexed, Cisplatin, Carboplatin. Conditions listed: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialA Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialStudy of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialStudy of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialA Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.